Unknown

Dataset Information

0

Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma.

ABSTRACT: Supplemental Digital Content is available in the text.

SUBMITTER: Houot R 

PROVIDER: S-EPMC8751801 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Gemcitabine, oxaliplatin and dexamethasone (GemDOx) as salvage therapy for relapsed or refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
| S-EPMC7738829 | biostudies-literature
Unknown Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
| S-EPMC3815173 | biostudies-literature
Unknown Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
| S-EPMC2735068 | biostudies-literature
Unknown PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
| S-EPMC4348009 | biostudies-literature
Unknown Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.
| S-EPMC7723809 | biostudies-literature
Unknown A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
| S-EPMC4830040 | biostudies-literature
Unknown Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
| S-EPMC4335079 | biostudies-literature
Unknown PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
| S-EPMC5766844 | biostudies-literature
Unknown An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
| S-EPMC6225348 | biostudies-literature
Unknown Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
| S-EPMC5193224 | biostudies-literature